Hapten

Global Conjugation and Labeling Services Market Report 2023-2035: Antibody Conjugation Services Lead Research Demand, Fuel Market Dominance - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 22, 2023
Biotechnology, General Health, Health, Pharmaceutical, Health Technology, Fluorescence, Administration, Hapten, Enzyme, Harvey, Polymer, Research, Element, Antibody, Proteomics, Labelling, Projection, Organization, Prominence, Quantum, SWOT, Protein, Outline, HRP, SWOT analysis, Growth, Conjugation, Bioconjugate Chemistry, Isotope, ChromeOS, Peptide, Fine chemical, Microscope, Marketing, Audit, Management, Retail, Risk management

As the demand for conjugated biomolecules escalates within research and development, the conjugation and labeling services market is poised for significant growth in the foreseeable future.

Key Points: 
  • As the demand for conjugated biomolecules escalates within research and development, the conjugation and labeling services market is poised for significant growth in the foreseeable future.
  • The report delves into an extensive study of the present market landscape and size, as well as the potential future trajectory of the conjugation and labeling services market throughout the forecast period.
  • The current market landscape is populated by over 170 companies offering antibody conjugation services and 120 providing protein labeling services worldwide.
  • Custom antibody conjugation for research purposes is the most sought-after service, encompassing options like HRP conjugation, Biotin Conjugation, and Fluorescent labeling.

Global Conjugation and Labeling Services Market to 2035: Rising Demand for Conjugated Biomolecules in the Field of Research and Development Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 12, 2023
Health, Pharmaceutical, Molecule, Bioconjugation, Therapy, Administration, Hapten, Enzyme, Polymer, Research, Antibody, Organization, Protein, Membrane, Conjugation, Bioconjugate Chemistry, Isotope, ChromeOS, Peptide, Fine chemical, Vaccine

The "Conjugation and Labeling Services Market: Focus on Protein Labeling, Peptide Labeling, Small Molecule Conjugation and Antibody Conjugation: Industry Trends and Global Forecasts, 2023-2035" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Conjugation and Labeling Services Market: Focus on Protein Labeling, Peptide Labeling, Small Molecule Conjugation and Antibody Conjugation: Industry Trends and Global Forecasts, 2023-2035" report has been added to ResearchAndMarkets.com's offering.
  • This report features an extensive study of the current market landscape, market size and the likely future potential of the conjugation and labeling services market, during the forecast period.
  • Further, given the rising demand for conjugated biomolecules in the field of research and development, the conjugation and labeling services market is anticipated to witness substantial growth in the foreseen future.
  • These factors together will be responsible for market growth through increased outsourcing of protein labeling, antibody labeling and antibody conjugation services to the CROs.

ATP and NYU Langone Health Launch Aethon Therapeutics to Eradicate Drug-Resistant Cancer Cells

Retrieved on: 
Monday, January 9, 2023
Cancer, Peptide, NYU Langone Health, Invention, Protein, Drug discovery, KRAS, Research, RAS, EGFR, Terra Venture Partners, Immunotherapy, Disease, Royal College of Pathologists, DRS, FRSB, MHC, FRCP, Hapten, Drug resistance, Antibody, Immune system, Margaret, Recurrence, Observation, NYU, ATP, Neoplasm, Pharmaceutical industry, Vaccine, Aethon, American Association for Cancer Research

NEW YORK, Jan. 9, 2023 /PRNewswire/ -- New therapies targeting oncogenic mutations in proteins such as RAS and EGFR hold great promise for people fighting cancer. However, their efficacy is limited by tumor cells' ability to develop resistance to these drugs, which can lead to disease recurrence.

Key Points: 
  • Today, Aethon Therapeutics launches to create novel antibodies designed to eliminate drug resistance by enabling the immune system to find and kill persistent cancer cells.
  • NYU Langone Health also participated in this funding round and holds equity in Aethon.
  • NYU Langone Health is the owner of the technology exclusively licensed to Aethon and has equity and other financial interests in Aethon.
  • Koide and Neel also have equity in Aethon, and Aethon is also sponsoring research conducted by Dr. Koide and Dr. Neel at NYU Langone Health.

BioVaxys Announces Successful Test-Run Production of its Bi-Haptenized Ovarian Cancer Vaccine

Retrieved on: 
Thursday, December 1, 2022
Marketing, COVID-19, Hapten, Flow cytometry, Ovarian tumor, IND, Cancer, GMP, Spanish, CTA, OTCQB, Investigational New Drug, CSE, Ovarian cancer, Clinical trial, Severe acute respiratory syndrome coronavirus 2, Trial of the century, Vaccine, FRA, FDA, EU

VANCOUVER, BC, Dec. 1, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF)("BioVaxys" or "Company") is pleased to announce the successful sterile and bacteria-free test-run production of BVX-0918, the Company's bi-haptenized autologous ovarian cancer vaccine.

Key Points: 
  • VANCOUVER, BC, Dec. 1, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF)("BioVaxys" or "Company") is pleased to announce the successful sterile and bacteria-free test-run production of BVX-0918, the Company's bi-haptenized autologous ovarian cancer vaccine.
  • BioVaxys President and Chief Operating Officer Kenneth Kovan stated, "BioVaxys has successfully met a major manufacturing milestone by establishing the process to take surgically excise ovarian cancer cells from a cancer patient, conjugate two haptens, and manufacture a sterile and bacteria-free complete vaccine.
  • BioVaxys has two issued US patents, and multiple US and international patent applications related to its cancer vaccines, antiviral vaccines, and diagnostic technologies.
  • BioVaxys common shares are listed on the CSE under the stock symbol "BIOV" and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB:BVAXF).

BioVaxys Announces Successful Test-Run Production of its Bi-Haptenized Ovarian Cancer Vaccine

Retrieved on: 
Thursday, December 1, 2022
Marketing, COVID-19, Hapten, Flow cytometry, Ovarian tumor, IND, Cancer, GMP, Spanish, CTA, OTCQB, Investigational New Drug, CSE, Ovarian cancer, Clinical trial, Severe acute respiratory syndrome coronavirus 2, Trial of the century, Vaccine, FRA, FDA, EU

VANCOUVER, BC, Dec. 1, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF)("BioVaxys" or "Company") is pleased to announce the successful sterile and bacteria-free test-run production of BVX-0918, the Company's bi-haptenized autologous ovarian cancer vaccine.

Key Points: 
  • VANCOUVER, BC, Dec. 1, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF)("BioVaxys" or "Company") is pleased to announce the successful sterile and bacteria-free test-run production of BVX-0918, the Company's bi-haptenized autologous ovarian cancer vaccine.
  • BioVaxys President and Chief Operating Officer Kenneth Kovan stated, "BioVaxys has successfully met a major manufacturing milestone by establishing the process to take surgically excise ovarian cancer cells from a cancer patient, conjugate two haptens, and manufacture a sterile and bacteria-free complete vaccine.
  • BioVaxys has two issued US patents, and multiple US and international patent applications related to its cancer vaccines, antiviral vaccines, and diagnostic technologies.
  • BioVaxys common shares are listed on the CSE under the stock symbol "BIOV" and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB:BVAXF).

Clinical Study Collaborator HCL Sends First Surgically Excised Ovarian Cancer Tumors to BioVaxys for BVX-0918 Vaccine Process Development

Retrieved on: 
Wednesday, June 15, 2022
FDA, COVID-19, Good, GMP, Vaccine, Cancer, FRA, Survival, Hapten, Company, HCL, Trial of the century, Hospices Civils de Lyon, Hospital, Neoplasm, OTCQB, CSE, Protein, Clinical trial, MD, Severe acute respiratory syndrome coronavirus 2, Immune system, IND, Ovarian cancer, Patient, Cryopreservation, Toxicity, Woman, Pharmaceutical industry, Medical imaging, BC, EU

BioVaxys recently entered collaborations with HCL and Deaconess Research Institute in the United States to provide the Company with surgically debulked tumors from Stage III/Stage IV ovarian cancer patients.

Key Points: 
  • BioVaxys recently entered collaborations with HCL and Deaconess Research Institute in the United States to provide the Company with surgically debulked tumors from Stage III/Stage IV ovarian cancer patients.
  • The identity assay will be performed on every batch of autologous ovarian cancer vaccine, and is mandatory for regulatory bodies in the EU and United States.
  • With the surgically excised tumors we can now begin the final stages of the vaccine production protocol and GMP validation."
  • BioVaxys has two issued US patents, and multiple US and international patent applications related to its cancer vaccines, antiviral vaccines, and diagnostic technologies.

Clinical Study Collaborator HCL Sends First Surgically Excised Ovarian Cancer Tumors to BioVaxys for BVX-0918 Vaccine Process Development

Retrieved on: 
Wednesday, June 15, 2022
FDA, COVID-19, Good, GMP, Vaccine, Cancer, FRA, Survival, Hapten, Company, HCL, Trial of the century, Hospices Civils de Lyon, Hospital, Neoplasm, OTCQB, CSE, Protein, Clinical trial, MD, Severe acute respiratory syndrome coronavirus 2, Immune system, IND, Ovarian cancer, Patient, Cryopreservation, Toxicity, Woman, Pharmaceutical industry, Medical imaging, BC, EU

BioVaxys recently entered collaborations with HCL and Deaconess Research Institute in the United States to provide the Company with surgically debulked tumors from Stage III/Stage IV ovarian cancer patients.

Key Points: 
  • BioVaxys recently entered collaborations with HCL and Deaconess Research Institute in the United States to provide the Company with surgically debulked tumors from Stage III/Stage IV ovarian cancer patients.
  • The identity assay will be performed on every batch of autologous ovarian cancer vaccine, and is mandatory for regulatory bodies in the EU and United States.
  • With the surgically excised tumors we can now begin the final stages of the vaccine production protocol and GMP validation."
  • BioVaxys has two issued US patents, and multiple US and international patent applications related to its cancer vaccines, antiviral vaccines, and diagnostic technologies.

Bio-Manufacturing Partner BioElpida Completes Next Phase of BVX-0918 GMP Production for EU Clinical Study

Retrieved on: 
Wednesday, June 8, 2022
Woman, Hospices Civils de Lyon, Fibroadenoma, CSE, Company, OTCQB, Neoplasm, Hapten, Survival, Toxicity, FRA, GMP, IND, Ovarian cancer, Cisplatin, Vaccine, FDA, Patient, Hospital, COVID-19, Trial of the century, Immune system, Severe acute respiratory syndrome coronavirus 2, MD, Clinical trial, Population, Cancer, HCL, Good, Cryopreservation, Immortalised cell line, Protein, Pharmaceutical industry, EU, BC

BioVaxys' vaccine platform is based on the established immunological concept that modifying surface proteins---whether they are viral or tumor---with haptens makes them more visible to the immune system. This process of haptenization "teaches" a patient's immune system to recognize and make target proteins more "visible" as foreign, thereby stimulating a T-cell mediated immune response. BioVaxys' cancer vaccines are created by extracting a patient's own (autologous) cancer cells, chemically linking with a hapten, and re-injecting them into the patient to induce an immune response to proteins which are otherwise not immunogenic. Haptenization is a well-known and well-studied immunotherapeutic approach to cancer immunotherapy and has been clinically evaluated in both regional and disseminated metastatic tumors.

Key Points: 
  • The OVCAR-3 cell line is mandatory for creating the identity assays that will have to be performed on every batch of ovarian cancer vaccine.
  • The cell line is derived from a human ovarian adenocarcinoma, established from a patient refractory to cisplatin, a chemotherapeutic agent used in late-stage ovarian cancer.
  • Patients whose tumors are innately cisplatin-resistant at the time of initial treatment generally have poor prognosis, which is the patient population target for BVX-0918.
  • ( www.biovaxys.com ) is aBritish Columbia-registered, clinical stage biotechnology company that is developing viral and oncology vaccine platforms, as well as immuno-diagnostics.

Bio-Manufacturing Partner BioElpida Completes Next Phase of BVX-0918 GMP Production for EU Clinical Study

Retrieved on: 
Wednesday, June 8, 2022
Woman, Hospices Civils de Lyon, Fibroadenoma, CSE, Company, OTCQB, Neoplasm, Hapten, Survival, Toxicity, FRA, GMP, IND, Ovarian cancer, Cisplatin, Vaccine, FDA, Patient, Hospital, COVID-19, Trial of the century, Immune system, Severe acute respiratory syndrome coronavirus 2, MD, Clinical trial, Population, Cancer, HCL, Good, Cryopreservation, Immortalised cell line, Protein, Pharmaceutical industry, EU, BC

BioVaxys' vaccine platform is based on the established immunological concept that modifying surface proteins---whether they are viral or tumor---with haptens makes them more visible to the immune system. This process of haptenization "teaches" a patient's immune system to recognize and make target proteins more "visible" as foreign, thereby stimulating a T-cell mediated immune response. BioVaxys' cancer vaccines are created by extracting a patient's own (autologous) cancer cells, chemically linking with a hapten, and re-injecting them into the patient to induce an immune response to proteins which are otherwise not immunogenic. Haptenization is a well-known and well-studied immunotherapeutic approach to cancer immunotherapy and has been clinically evaluated in both regional and disseminated metastatic tumors.

Key Points: 
  • The OVCAR-3 cell line is mandatory for creating the identity assays that will have to be performed on every batch of ovarian cancer vaccine.
  • The cell line is derived from a human ovarian adenocarcinoma, established from a patient refractory to cisplatin, a chemotherapeutic agent used in late-stage ovarian cancer.
  • Patients whose tumors are innately cisplatin-resistant at the time of initial treatment generally have poor prognosis, which is the patient population target for BVX-0918.
  • ( www.biovaxys.com ) is aBritish Columbia-registered, clinical stage biotechnology company that is developing viral and oncology vaccine platforms, as well as immuno-diagnostics.

BioVaxys Confirms First Clinical Site and Principal Investigators for Ovarian Cancer Vaccine Trial and Enters into Second Tumor Cell Supply Agreement

Retrieved on: 
Wednesday, May 18, 2022
Cancer, Hapten, Disease, HCL, Ovarian cancer, European Society of Gynaecological Oncology, Center, EMA, Standard of care, Immune system, FRA, OTCQB, University Hospital Center Dr Dragiša Mišović, GMP, Woman, Clinical trial, COVID-19, CSE, III, Hospital, Neoplasm, Company, Survival, Peritoneum, Doctor of Philosophy, Vaccine, Trial of the century, FDA, Obstetrics, Biotechnology, Good, Toxicity, CTA, European Medicines Agency, Heart, Hospices Civils de Lyon, Protein, Severe acute respiratory syndrome coronavirus 2, Cryopreservation, Patient, International Journal of Gynecology & Obstetrics, National Cancer Institute, IND, European Society for Clinical Investigation, Prognosis, Head, ProCare, Usha Menon, Pharmaceutical industry, Medical imaging, Lyon Metropolis, MD, EU, BC

HCL is a public hospital and France's second University Hospital Center, and a premier site for clinical studies in the EU.

Key Points: 
  • HCL is a public hospital and France's second University Hospital Center, and a premier site for clinical studies in the EU.
  • Benot You, MD, PhD, of HCL who are planned Clinical Investigators for the Phase I study of BVX-0918.
  • BioVaxys is preparing to file a Clinical Trial Application ("CTA") with the European Medicines Agency ("EMA") later in 2022.
  • Access to surgically removed ovarian cancer tumor cells is a critical step enabling BioVaxys to validate the manufacturing process for BVX-0918.